Get Ready for Hep C Meds Mavyret and Vosevi
October 2017
You'll see big changes in treating hepatitis C due to the new oral antivirals, Mavyret and Vosevi.
Expect to get more involved in managing hep C...just like you're managing heart disease, diabetes, etc. The newer hep C meds are easier to initiate, require less monitoring, and are better tolerated.
Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote